JAZZ Jazz Pharmaceuticals plc

-1.54  -1%
Previous Close 142.1
Open 140.21
Price To Book 2.8
Market Cap 8478802690
Shares 60,321,590
Volume 783,273
Short Ratio
Av. Daily Volume 709,475

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163849
  2. 8-K - Current report 181163064
  3. 8-K - Current report 181118653
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998964
  5. 8-K - Current report 18998040

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 4Q 2018.
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
Phase 2 enrollment initiation announced February 8, 2017.
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
Excessive sleepiness associated with obstructive sleep apnea
PDUFA date December 20, 2018.
Excessive sleepiness associated with narcolepsy
Phase 3 dosing initiation announced January 18, 2017.
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Acute myeloid leukemia
Phase 2 commencement of enrollment announced February 23, 2018.
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
Idiopathic Hypersomnia

Latest News

  1. Jazz (JAZZ) Increases Share Buyback Authorization by $400M
  2. The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
  3. All That JAZZ
  4. Jazz Pharmaceuticals Public Limited Company (JAZZ): Are Hedge Funds Right About This Stock?
  5. Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million
  6. Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) CEO Salary Justified?
  7. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
  8. Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting
  9. Edited Transcript of JAZZ earnings conference call or presentation 6-Nov-18 9:30pm GMT
  10. Where Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand
  11. Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
  12. Jazz Pharmaceuticals: A Financial Overview in November
  13. Jazz Pharmaceuticals: Analysts’ View in November
  14. Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ)
  15. Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
  16. Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View
  17. IBD 50 Pharma Stock Topples As Cancer Drug Lags Expectations
  18. This 99 Composite Rating Pharma Tumbled On Quarterly Sales Lag